UTHR.NASDAQUnited Therapeutics CORP
Form 4: UNITED THERAPEUTICS CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 15, 2026.
Summary
- Option exercise/conversion: acquired 1,718 Common Stock at $135.42 ($232,652) on July 15, 2026; holds 42,231 after (Direct).
- Open-market sale: disposed of 80 Common Stock at $521.82 ($41,746) on July 15, 2026; holds 42,151 after (Direct).
- Open-market sale: disposed of 120 Common Stock at $523.97 ($62,877) on July 15, 2026; holds 42,031 after (Direct).
- Open-market sale: disposed of 80 Common Stock at $525.42 ($42,034) on July 15, 2026; holds 41,951 after (Direct).
- Open-market sale: disposed of 40 Common Stock at $527.55 ($21,102) on July 15, 2026; holds 41,911 after (Direct).
- Open-market sale: disposed of 120 Common Stock at $529.66 ($63,560) on July 15, 2026; holds 41,791 after (Direct).
- Open-market sale: disposed of 278 Common Stock at $530.97 ($147,609) on July 15, 2026; holds 41,513 after (Direct).
- Open-market sale: disposed of 800 Common Stock at $532.06 ($425,647) on July 15, 2026; holds 40,713 after (Direct).
- Open-market sale: disposed of 160 Common Stock at $533.22 ($85,315) on July 15, 2026; holds 40,553 after (Direct).
- Open-market sale: disposed of 40 Common Stock at $534.09 ($21,364) on July 15, 2026; holds 40,513 after (Direct).
- Option exercise/conversion: acquired 7,782 Common Stock at $135.42 ($1,053,838) on July 15, 2026; holds 332,225 after (Indirect).
- Open-market sale: disposed of 48 Common Stock at $520.92 ($25,004) on July 15, 2026; holds 332,177 after (Indirect).
- Open-market sale: disposed of 189 Common Stock at $521.84 ($98,628) on July 15, 2026; holds 331,988 after (Indirect).
- Open-market sale: disposed of 203 Common Stock at $523.20 ($106,210) on July 15, 2026; holds 331,785 after (Indirect).
- Open-market sale: disposed of 440 Common Stock at $524.40 ($230,734) on July 15, 2026; holds 331,345 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $525.24 ($147,066) on July 15, 2026; holds 331,065 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $527.77 ($63,332) on July 15, 2026; holds 330,945 after (Indirect).
- Open-market sale: disposed of 641 Common Stock at $529.03 ($339,106) on July 15, 2026; holds 330,304 after (Indirect).
- Open-market sale: disposed of 577 Common Stock at $530.12 ($305,878) on July 15, 2026; holds 329,727 after (Indirect).
- Open-market sale: disposed of 1,044 Common Stock at $531.03 ($554,391) on July 15, 2026; holds 328,683 after (Indirect).
- Open-market sale: disposed of 3,295 Common Stock at $531.97 ($1,752,834) on July 15, 2026; holds 325,388 after (Indirect).
- Open-market sale: disposed of 825 Common Stock at $533.08 ($439,791) on July 15, 2026; holds 324,563 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $534.27 ($64,113) on July 15, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 1,718 Stock Option on July 15, 2026 (Direct).
- Option exercise/conversion: disposed of 7,782 Stock Option on July 15, 2026; holds 341,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,038,340 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-15 | Option exercise/conversion | Common Stock | 1,718 | $135 | $232.7K | 42,231 |
| 2026-07-15 | Open-market sale | Common Stock | 80 | $522 | $41.7K | 42,151 |
| 2026-07-15 | Open-market sale | Common Stock | 120 | $524 | $62.9K | 42,031 |
| 2026-07-15 | Open-market sale | Common Stock | 80 | $525 | $42.0K | 41,951 |
| 2026-07-15 | Open-market sale | Common Stock | 40 | $528 | $21.1K | 41,911 |
| 2026-07-15 | Open-market sale | Common Stock | 120 | $530 | $63.6K | 41,791 |
| 2026-07-15 | Open-market sale | Common Stock | 278 | $531 | $147.6K | 41,513 |
| 2026-07-15 | Open-market sale | Common Stock | 800 | $532 | $425.6K | 40,713 |
| 2026-07-15 | Open-market sale | Common Stock | 160 | $533 | $85.3K | 40,553 |
| 2026-07-15 | Open-market sale | Common Stock | 40 | $534 | $21.4K | 40,513 |
| 2026-07-15 | Option exercise/conversion | Common Stock | 7,782 | $135 | $1.1M | 332,225 |
| 2026-07-15 | Open-market sale | Common Stock | 48 | $521 | $25.0K | 332,177 |
| 2026-07-15 | Open-market sale | Common Stock | 189 | $522 | $98.6K | 331,988 |
| 2026-07-15 | Open-market sale | Common Stock | 203 | $523 | $106.2K | 331,785 |
| 2026-07-15 | Open-market sale | Common Stock | 440 | $524 | $230.7K | 331,345 |
| 2026-07-15 | Open-market sale | Common Stock | 280 | $525 | $147.1K | 331,065 |
| 2026-07-15 | Open-market sale | Common Stock | 120 | $528 | $63.3K | 330,945 |
| 2026-07-15 | Open-market sale | Common Stock | 641 | $529 | $339.1K | 330,304 |
| 2026-07-15 | Open-market sale | Common Stock | 577 | $530 | $305.9K | 329,727 |
| 2026-07-15 | Open-market sale | Common Stock | 1,044 | $531 | $554.4K | 328,683 |
| 2026-07-15 | Open-market sale | Common Stock | 3,295 | $532 | $1.8M | 325,388 |
| 2026-07-15 | Open-market sale | Common Stock | 825 | $533 | $439.8K | 324,563 |
| 2026-07-15 | Open-market sale | Common Stock | 120 | $534 | $64.1K | 324,443 |
| 2026-07-15 | Option exercise/conversion | Stock Option | 1,718 | — | — | 0 |
| 2026-07-15 | Option exercise/conversion | Stock Option | 7,782 | — | — | 341,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Option exercise/conversion (1,718 shares) |
| 2026-07-15 | Open-market sale (80 shares) |
| 2026-07-15 | Open-market sale (120 shares) |
| 2026-07-15 | Open-market sale (80 shares) |
| 2026-07-15 | Open-market sale (40 shares) |
| 2026-07-15 | Open-market sale (120 shares) |
| 2026-07-15 | Open-market sale (278 shares) |
| 2026-07-15 | Open-market sale (800 shares) |
| 2026-07-15 | Open-market sale (160 shares) |
| 2026-07-15 | Open-market sale (40 shares) |
| 2026-07-15 | Option exercise/conversion (7,782 shares) |
| 2026-07-15 | Open-market sale (48 shares) |
| 2026-07-15 | Open-market sale (189 shares) |
| 2026-07-15 | Open-market sale (203 shares) |
| 2026-07-15 | Open-market sale (440 shares) |
| 2026-07-15 | Open-market sale (280 shares) |
| 2026-07-15 | Open-market sale (120 shares) |
| 2026-07-15 | Open-market sale (641 shares) |
| 2026-07-15 | Open-market sale (577 shares) |
| 2026-07-15 | Open-market sale (1,044 shares) |
| 2026-07-15 | Open-market sale (3,295 shares) |
| 2026-07-15 | Open-market sale (825 shares) |
| 2026-07-15 | Open-market sale (120 shares) |
| 2026-07-15 | Option exercise/conversion (1,718 shares) |
| 2026-07-15 | Option exercise/conversion (7,782 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.